Maha Radhakrishnan
About Maha Radhakrishnan
Maha Radhakrishnan, M.D., is an independent Class III director of Entrada Therapeutics (TRDA) appointed effective June 1, 2025; she serves on the Audit Committee and will hold office until the 2027 annual meeting unless a successor is elected earlier . She is Executive Partner at Sofinnova Investments (since Aug 2024) and formerly Biogen’s Group SVP & Chief Medical Officer (Jan 2020–Mar 2024) and Sanofi’s SVP & Global Head of Medical, Primary Care BU (Oct 2018–Jan 2020) . Dr. Radhakrishnan earned her M.D. in internal medicine with honors from People’s Friendship University, Moscow, and a Master’s degree in Russian language . She is currently listed on TRDA’s registration statement signatures as a director (Nov 6, 2025), confirming status in good standing .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Biogen, Inc. | Group SVP & Chief Medical Officer; led worldwide medical function | Jan 2020 – Mar 2024 | Global medical leadership across portfolio |
| Sanofi S.A. | SVP & Global Head of Medical, Primary Care BU | Oct 2018 – Jan 2020 | Led medical strategy in primary care |
| Bioverativ; Bristol Myers Squibb; UnitedHealth Group; Cephalon | Various senior leadership roles | Prior to 2018 | Drug development, medical affairs, payer/healthcare exposure |
| Sofinnova Investments | Executive Partner | Since Aug 2024 | Diligence across clinical-ready assets; portfolio development guidance |
External Roles
| Organization | Type | Role | Tenure |
|---|---|---|---|
| Alto Neuroscience, Inc. | Public, clinical-stage biopharma | Director | Mar 2024 – May 2025 |
| Minovia Therapeutics | Private biotech | Director | Since Jan 2023 |
| Sofinnova Investments | VC (life sciences) | Executive Partner | Since Aug 2024 |
Board Governance
- Board expanded from six to seven directors; Radhakrishnan appointed Class III director effective June 1, 2025 .
- Audit Committee: Radhakrishnan appointed, replacing Kush Parmar; compositions of Nominating & Corporate Governance and Compensation Committees unchanged; Audit Committee is chaired by Mary Thistle per latest proxy .
- Independence: Board determined Radhakrishnan is independent under Nasdaq standards; no related-party transactions (Item 404) and no family relationships disclosed .
- Board leadership: Chairman role (Kush M. Parmar) is separate from CEO, consistent with governance practices; board oversees risk primarily through committees .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Board Retainer (cash) | $40,000 | Per Third Amended & Restated Non-Employee Director Compensation Policy |
| Audit Committee Member Retainer (cash) | $9,000 | Effective with appointment to Audit Committee |
- Indemnification: Entered Company’s standard indemnification agreement (filed as Exhibit 10.4 to S-1) .
- Expense reimbursement: Company reimburses reasonable out-of-pocket board meeting expenses under director policy .
Performance Compensation
| Equity Award | Size | Value cap | Vesting | Notes |
|---|---|---|---|---|
| Initial stock option grant (on appointment) | Up to 38,000 shares | Lesser of $500,000 Black-Scholes value or 38,000 shares | Equal monthly installments over 3 years, subject to continuous service | Granted effective June 1, 2025 |
| Annual stock option grant (each Annual Meeting, starting 2026) | Up to 19,000 shares | Lesser of $250,000 Black-Scholes value or 19,000 shares | Vests in full on earlier of 1-year or next Annual Meeting, subject to continuous service | Policy terms applicable while serving |
| Change-of-control acceleration | N/A | N/A | Full acceleration upon sale of company, or upon death/disability | As provided in TRDA’s non-employee director compensation policy |
No performance metrics (e.g., TSR, clinical milestones) are tied to director equity per disclosed policy; vesting is time-based for annual grants and time-based monthly for initial grant .
Other Directorships & Interlocks
| Relationship | Potential Interlock/Conflict Consideration |
|---|---|
| Alto Neuroscience (public) board service ended May 2025 | Historical public board service; no TRDA related-party transactions disclosed |
| Minovia Therapeutics (private) board | Private company role; no TRDA related-party transactions disclosed |
| Executive Partner, Sofinnova Investments | VC affiliation; Company disclosed independence and no related-party transactions with TRDA |
Expertise & Qualifications
- Drug development leadership: Former CMO at Biogen; senior medical leadership roles at Sanofi; extensive development and commercialization expertise across multiple therapeutic areas .
- Strategic diligence: Leads clinical-ready asset diligence and portfolio support at Sofinnova; brings investor and operator perspectives .
- Education: M.D. in internal medicine (honors) and Master’s in Russian language from People’s Friendship University .
Equity Ownership
| Item | Status |
|---|---|
| Beneficial ownership at TRDA | Not disclosed in 2025 proxy; appointment mid-2025; S-3 signature confirms board status . |
| Insider trading/hedging policy | Company policy prohibits hedging and derivative transactions; highlights risks of margin/pledging arrangements . |
| Related-party transactions | None disclosed for Radhakrishnan; board confirmed independence . |
Governance Assessment
- Board effectiveness: Adds seasoned global drug-development executive to Audit Committee, strengthening oversight as TRDA advances Duchenne programs .
- Independence and conflicts: Board affirmatively determined independence; no related-party transactions, family relationships, or appointment arrangements disclosed—a positive signal for governance quality .
- Compensation alignment: Cash retainer modest; equity-heavy compensation (initial and annual option grants) promotes ownership alignment. Note the share-cap increase versus prior proxy policy (from 32,000/16,000 shares to 38,000/19,000 shares), indicating higher equity awards for non-employee directors—a potential pay inflation risk to monitor .
- Attendance/engagement: Appointed mid-2025; no individual attendance metrics disclosed yet. Company-wide, directors met attendance expectations in 2024 (≥75% of meetings), and maintains separate Chair/CEO roles and robust committee charters—supportive of oversight .
RED FLAGS
- Increased equity grant share caps for non-employee directors vs. prior policy could indicate compensation inflation; monitor subsequent proxy disclosures and equity burn rate .
- VC affiliation (Sofinnova) warrants ongoing review for potential related-party transactions; currently none disclosed and independence affirmed .